The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Tecvayli teclistamab PRIMEAdditional monitoring | Multiple Myeloma | 🇪🇺 EU 2022-08-23 | Order → | |
| Pepaxti melphalan flufenamide | Oncopeptides AB (publ) | Multiple Myeloma | 🇪🇺 EU 2022-08-17 | Order → |
| Rayvow lasmiditan Additional monitoring | Eli Lilly Nederland B.V. | Migraine Disorders | 🇪🇺 EU 2022-08-17 | Order → |
| Sunlenca lenacapavir Additional monitoring | Gilead Sciences Ireland Unlimited Company | HIV Infections | 🇪🇺 EU 2022-08-17 | Order → |
| Vegzelma bevacizumab BiosimilarAdditional monitoring | Celltrion Healthcare Hungary Kft. | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2022-08-17 | Order → |
| Vyvgart efgartigimod alfa OrphanAdditional monitoring | Argenx | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 🇪🇺 EU 2022-08-10 | Order → |
| Sitagliptin / Metformin hydrochloride Accord sitagliptin;metformin hydrochloride Generic | Accord Healthcare S.L.U. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2022-07-22 | Order → |
| Upstaza eladocagene exuparvovec OrphanATMPExceptional circumstances | PTC Therapeutics International Limited | Amino Acid Metabolism, Inborn Errors | 🇪🇺 EU 2022-07-18 | Order → |
| Zokinvy lonafarnib OrphanExceptional circumstancesAdditional monitoring | Integral Pharma Solutions EU Limited | Progeria; Laminopathies | 🇪🇺 EU 2022-07-18 | Order → |
| Cevenfacta eptacog beta (activated) Additional monitoring | Laboratoire Francais du Fractionnement et des Biotechnologies | Hemophilia A; Hemophilia B | 🇪🇺 EU 2022-07-15 | Order → |
| Ertapenem SUN ertapenem Generic | SUN Pharmaceutical Industries (Europe) B.V. | Bacterial Infections | 🇪🇺 EU 2022-07-15 | Order → |
| Ganirelix Gedeon Richter ganirelix Generic | Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.) | Reproductive Techniques, Assisted; Ovulation Induction; Infertility, Female | 🇪🇺 EU 2022-07-15 | Order → |
| Kinpeygo budesonide Orphan | Stada Arzneimittel AG | Glomerulonephritis, IGA | 🇪🇺 EU 2022-07-15 | Order → |
| Sugammadex Fresenius Kabi sugammadex Generic | Fresenius Kabi Deutschland GmbH | Neuromuscular Blockade | 🇪🇺 EU 2022-07-15 | Order → |
| COVID-19 Vaccine (inactivated, adjuvanted) Valneva COVID-19 vaccine (inactivated, adjuvanted, adsorbed) Additional monitoring | Valneva Austria GmbH | COVID-19 virus infection | 🇪🇺 EU 2022-06-24 | Order → |
| Nexviadyme avalglucosidase alfa Additional monitoring | Sanofi B.V. | Glycogen Storage Disease Type II | 🇪🇺 EU 2022-06-24 | Order → |
| Xenpozyme olipudase alfa OrphanPRIMEAdditional monitoring | Sanofi B.V. | Acid sphingomyelinase deficiency (ASMD) type A/B or type B | 🇪🇺 EU 2022-06-24 | Order → |
| Filsuvez birch bark extract Orphan | Chiesi Farmaceutici S.p.A | Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional | 🇪🇺 EU 2022-06-21 | Order → |
| Pirfenidone axunio (previously Pirfenidone AET) pirfenidone Generic | Axunio Pharma GmbH | Idiopathic Pulmonary Fibrosis | 🇪🇺 EU 2022-06-20 | Order → |
| Tabrecta capmatinib Additional monitoring | Novartis Europharm Limited | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2022-06-20 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.